# The Neuro & Alzheimer's Pipeline - Week of June 21, 2026: uniQure's Huntington's Gene Therapy Wins FDA Submission Path

> Neuro and Alzheimer's pipeline newsletter for the week of June 21, 2026. uniQure won a clear FDA path to a Q3 2026 Huntington's gene-therapy filing after a leadership change at the agency, while the anti-amyloid story stayed quiet on the tape and the blood-diagnostic funnel kept widening.

## The Neuro & Alzheimer's Pipeline

### Week of June 21, 2026: uniQure's Huntington's Gene Therapy Wins FDA Submission Path

---

## TL;DR

- **uniQure's Huntington's gene therapy got a clear FDA path this week**, submission coming in Q3 2026 for accelerated approval, after the Makary/Prasad-era "data insufficient" verdict was reversed once those two left the agency. The single most market-relevant CNS headline of the week.
- **The anti-amyloid story has gone quiet on the tape but loud in the clinic.** The only fresh primary-source detail on Leqembi/Kisunla came from CME programs run by treating clinicians, not management or sell-side. Their message: the drugs work modestly, the diagnostic plumbing is finally improving, and reimbursement for blood tests is still the gating item.
- **It was a thin week for the megacaps.** No fresh podcast coverage of Lilly Kisunla launch metrics, Biogen/Eisai Leqembi sales, Roche trontinemab, AbbVie neuro, or the imaging names. Don't read silence as a signal, read it as a slow news week into summer.

## What's new

**1. The FDA blinked on uniQure's Huntington's gene therapy, and the regime change matters.** On [The Readout Loud, Ep. 406 (June 18)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgEvZiqBJAm67eJczEWQ1lnQ9xc8jHe67fJBzJc19n0oj2-2Fg8RBytAew4NGWI2JOARsy0JhAsZahVflaE8NP9KilLWF6zxXxq7cgsOL8CfznQ-3D-3D-rPz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXADaDPJRGdI6NTl-2Bak8BVzGQHrd24Kp2teUy9NT2ddlPOYmdJfC2rKct5knsiliVyT9F3uBZFYgG85Yhlmj0ZWTlnTyTfTazNt63QGd4H7TJiy6tsUco-2FI73UMdGWGgzwZGgJ7fAgXcXog4rfnIH2jdK78-2Fz3UUelPCDRUe8ki6w-3D-3D), STAT's **Adam Feuerstein** and **Allison DeAngelis** *(PUNDIT/journalist)* walked through the week's only genuinely new development: uniQure and the FDA "hammered out an agreement that clears a path" for the company to file its Huntington's gene therapy, with a submission targeted for **Q3 of this year** under accelerated approval plus a confirmatory trial. The backstory is the story: data showed the treatment **slowed Huntington's progression by ~75% after three years**, the prior FDA under Marty Makary and Vinay Prasad had called that "insufficient," and the path only opened after both men left the agency. **Why it moves numbers:** this is the first credibly disease-modifying shot at Huntington's, and the read-through (that the current FDA is more willing to engage on small-N neurodegeneration datasets) is bullish for the entire CNS rare-disease complex.

**2. Anti-amyloid efficacy: still "delay, not improve," straight from the people infusing it.** On the [PeerView Neuroscience & Psychiatry CME program with Jordan Mast, PA-C (June 15)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgNjzQnUracmQDHPXl9tGgQkTGwVRSGly1Bh9zCZyLJ-2BwaN88PC9FG4mFISflCKJqGpU95nt5-2FqgHT5IopMd25OSs4JMlDiEvBDj6R-2FfI-2B-2FPg-3D-3Dixwh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXADaDPJRGdI6NTl-2Bak8BVzGQHrd24Kp2teUy9NT2ddlCDMYfHw-2FjTMwyQfGb0rtcJtcJOmCoIEHxlCB-2FSh-2FJNoz5pqlFNuwCcPaAcfZPP64aQsNWmJ0XdIzLlP-2BRX1eXdaRZHx675wdWhPT4aNfdbuiH6ZlMgXk4-2FW7-2FW9WGIDwQ-3D-3D), a Washington University–St. Louis clinical panel *(OPERATOR/clinician-at-point-of-care)* laid out the live treatment reality. Kisunla's (donanemab's) differentiated feature is durability: patients hit amyloid-negative on PET in **~30% by 6 months, 66% by 12 months, and 76–77% by 18 months**, at which point **treatment can stop indefinitely**, a real cost-of-therapy advantage over Leqembi's chronic q2-week dosing (which drops to q4-weekly after 18 months). They also flagged that **Lilly modified the donanemab titration schedule in July 2025** to a slower ramp over the first three months to blunt ARIA. **Why it matters:** the "you can stop the drug" pitch is the commercial wedge for Kisunla, but the panel was blunt that none of this *improves* cognition, it delays decline.

**3. The diagnostic bottleneck is the actual swing factor, and it's loosening.** On the [PeerView Neuroscience & Psychiatry CME program with Amy Klingler, PA-C (June 15)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjKXhPgQj-2FqoQzjop2G3kAOwP9-2BWCcAd8-2ByMLCdFPduZjN9P-2B20D5ZIzT-2B58QDOcBHMI4vtaDfez97qT5hsXz8dSdVU1TmD9bhLsF-2FH2HplAQ-3D-3DZP1U_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXADaDPJRGdI6NTl-2Bak8BVzGQHrd24Kp2teUy9NT2ddlKpGBXk-2B7tpyb5Viud7nuVFw5fqyjtbj2rh8q6hUcbcK92IO-2FZ-2Bmoix0CB5zyK1cDrfqncPwD0SHuWUDtLg-2B74tEtKtZXXVsPZ2iONbhkNEe8LjTmijYSQZmYx-2FLa8gCBw-3D-3D), the panel *(OPERATOR/clinician)* dropped the number that should anchor every diagnostics model: adding blood-based biomarkers to standard cognitive screening in primary care **cut specialty-care wait times from 50 months to 12 months**. They also noted clinical diagnosis is wrong **40% of the time in primary care and 25% in specialty care** without biomarkers, and biomarkers push accuracy above 90%. The named tests in clinical use: **Roche's Elecsys pTau-181** (approved Oct 2025 as a primary-care triaging test, ~90% sensitivity/75% specificity), **Fujirebio's Lumipulse pTau-217/Aβ42** (approved May 2025 for specialty care), and **C2N's PrecivityAD2** (the APS2 score), which the WashU group said it uses to *start* therapy. The catch, per the same panel: **blood tests still aren't reliably reimbursed by Medicare.** That's the gate.

## The debate

**Bull case (multi-billion franchise):** Sub-Q dosing, a fast-improving blood-test funnel, and a more accommodating FDA collapse the friction that has throttled uptake. The clinicians themselves confirmed the funnel math, 50 months of wait time down to 12, and confirmed they're now treating APOE4/4 homozygotes (the highest-ARIA group) rather than excluding them. If diagnosis stops being a 40-month bottleneck, the addressable pool expands fast.

**Bear case (structurally weak):** The drugs *delay*, they don't reverse. The WashU panel was explicit that ARIA management requires baseline plus four screening MRIs and a good neuroradiologist, infrastructure most of America doesn't have. And the single most important reimbursement item, Medicare coverage of blood biomarkers, **still isn't there.** Meanwhile the tau and non-amyloid bets that are supposed to be the next leg (E2814, remternetug, trontinemab, bepranemab) generated **zero** podcast discussion this week, unproven and, this week, unmentioned.

> *"It delays the progression. It does not improve their symptoms. It does not stop progression."* (Jordan Mast's panel, on the honest framing every PM should hold in their head.)

## Stocks in play

- **Eli Lilly (LLY):** *Bull:* Kisunla's "treat-to-target, then stop" durability (76–77% amyloid-negative by 18 months) is a genuine cost-of-therapy edge; Lilly also owns the Avid PET tracer franchise. *Bear:* modest efficacy, ARIA logistics, no launch metrics on the tape this week. *Next catalyst:* sub-Q donanemab data/regulatory progress.
- **Biogen (BIIB) / Eisai:** *Bull:* Leqembi first-mover, IQLIK sub-Q maintenance for persistence. *Bear:* chronic q2-week IV burden vs. Kisunla's stop rule; no fresh ramp data this week. *Next catalyst:* quarterly Leqembi run-rate and sub-Q uptake.
- **Roche (RHHBY):** *Bull:* arguably the best-positioned diagnostics franchise via the Elecsys pTau-181 triaging test now in primary care; trontinemab is the brain-shuttle wildcard. *Bear:* no trontinemab update this week. *Next catalyst:* trontinemab Phase II readouts.
- **uniQure (QURE):** *Bull:* clear FDA path to a Q3 2026 Huntington's filing with a 75%/3-year slowing dataset. *Bear:* accelerated approval + confirmatory trial = the data debate isn't over. *Next catalyst:* the Q3 submission itself.
- **AbbVie (ABBV):** in the franchise (emraclidine, Vyalev, Cerevel assets) but **no coverage this week.**

## Read-throughs

- **Blood diagnostics:** the most actionable theme this week. Roche (Elecsys pTau-181), Fujirebio/H.U. Group (Lumipulse pTau-217), and C2N (PrecivityAD2) are all in active clinical use per the WashU panel, but **Medicare reimbursement remains the unlock.** No mention of **Quanterix (QTRX)** this week.
- **PET imaging (LNTH, GEHC):** PET remains the "gold standard" confirmatory step the clinicians lean on after a positive blood triage, structurally supportive, but **neither Lantheus nor GE HealthCare was named** in any episode this week.
- **Infusion centers / specialty pharmacy (OPCH):** **no coverage.** The IV-administration burden that underpins the infusion thesis was discussed clinically, but no names.
- **Rare-disease/gene therapy read-through:** the uniQure outcome is the cleanest positive, a friendlier FDA on small neurodegeneration datasets helps the broader CNS gene-therapy cohort.

## What changed vs. last week

The headline shift is **regulatory, not commercial**: the same uniQure dataset the prior FDA leadership rejected now has a submission path purely because the agency's leadership changed, an explicit walk-back of the earlier "insufficient data" stance, per STAT's reporting. On the Alzheimer's side, **nothing changed on the numbers**, no new launch figures, no guidance revisions, no new tau data. The only durable update is the steady drumbeat that the **diagnostic funnel is widening** (50→12 month wait times) while **reimbursement lags.** Quiet week on the megacaps; loud week for Huntington's.

*Coverage note: no podcast episodes in the June 14–21 window discussed Lilly Kisunla launch metrics, Biogen/Eisai Leqembi sales or international rollout, Roche trontinemab/bepranemab, AbbVie neuroscience, the tau/non-amyloid programs (E2814, remternetug, BIIB080, ACI-35, TREM2), Quanterix, the PET imaging names (Lantheus, GE HealthCare), CMS NCD/prior-auth mechanics, KarXT/Cobenfy, or infusion centers (OPCH). Nothing has been invented to fill those gaps.*